INFLUENCE OF NEUROLOGIC MANIFESTATIONS OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION ON DISEASE PROGRESSION

被引：58

作者：

BOUFASSA, F ^{[1
]}

BACHMEYER, C ^{[1
]}

CARRE, N ^{[1
]}

DEVEAU, C ^{[1
]}

PERSOZ, A ^{[1
]}

JADAND, C ^{[1
]}

SERENI, D ^{[1
]}

BUCQUET, D ^{[1
]}

ROUZIOUX, C ^{[1
]}

DELLAMONICA, P ^{[1
]}

GALLAIS, H ^{[1
]}

DELFRAISSY, JF ^{[1
]}

LEFRERE, JJ ^{[1
]}

CASSUTO, JP ^{[1
]}

DUPONT, B ^{[1
]}

VITTECOQ, D ^{[1
]}

HERSON, S ^{[1
]}

GASTAUT, JA ^{[1
]}

VILDE, JL ^{[1
]}

KATLAMA, C ^{[1
]}

SOBEL, A ^{[1
]}

DUVAL, J ^{[1
]}

KAZATCHKINE, M ^{[1
]}

LEBRAS, P ^{[1
]}

EVEN, P ^{[1
]}

GUILLEVIN, L ^{[1
]}

MEYER, L ^{[1
]}

DEVEAU, C ^{[1
]}

机构：

[1] HOP COCHIN, DEPT MED INTERNE, Cochin, FRANCE

来源：

JOURNAL OF INFECTIOUS DISEASES | 1995年 / 171卷 / 05期

关键词：

D O I：

10.1093/infdis/171.5.1190

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To determine the influence of neurologic manifestations of primary human immunodeficiency virus (HIV) infection on disease progression, 277 nonhemophiliac adults enrolled <1 year after HIV infection were studied, Patients with neurologic manifestations during symptomatic primary HIV infection (PSI) (group N+; n = 23), with nonneurologic manifestations (group N-; n = 112) during PSI, and without any clinical manifestation during primary infection (group NPI; n = 142) were compared for disease progression, Age at infection, sex, mode of infection and CD4(+) cell count at first visit did not differ between groups, In a Cox model, the relative risk (RR) of developing AIDS was 6.11 (95% confidence interval [CI], 1.94-19.28) in group Nf and 2.32 (95% CI, 0.93-5.83) in group N- compared with group NPI, The RR of AIDS onset after adjustment for treatment and age at infection was, respectively, 4.65 (95% CI, 1.43-15.03) and 2.03 (95% CI, 0.80-5.19) in groups N+ and N-, Neurologic manifestations of primary HIV infection are associated with an accelerated progression of disease.

引用

页码：1190 / 1195

页数：6

共 30 条

[1] RAPID DEVELOPMENT OF ISOLATE-SPECIFIC NEUTRALIZING ANTIBODIES AFTER PRIMARY HIV-1 INFECTION AND CONSEQUENT EMERGENCE OF VIRUS VARIANTS WHICH RESIST NEUTRALIZATION BY AUTOLOGOUS SERA [J].